These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 11107110)

  • 21. [«Malignant stroma?» Alternative localization of classical genetic aberrations in neuroblastoma].
    Sharlai AS; Gegeliya NV; Druy AE; Konovalov DM
    Arkh Patol; 2023; 85(4):47-53. PubMed ID: 37530190
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Allelotype of neuroblastoma.
    Takita J; Hayashi Y; Kohno T; Shiseki M; Yamaguchi N; Hanada R; Yamamoto K; Yokota J
    Oncogene; 1995 Nov; 11(9):1829-34. PubMed ID: 7478611
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Deletion of chromosome 1p loci and microsatellite instability in neuroblastomas analyzed with short-tandem repeat polymorphisms.
    Martinsson T; Sjöberg RM; Hedborg F; Kogner P
    Cancer Res; 1995 Dec; 55(23):5681-6. PubMed ID: 7585654
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Kidins220/ARMS depletion is associated with the neural-to Schwann-like transition in a human neuroblastoma cell line model.
    Rogers DA; Schor NF
    Exp Cell Res; 2013 Mar; 319(5):660-9. PubMed ID: 23333500
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Schwann cell-conditioned medium inhibits angiogenesis.
    Huang D; Rutkowski JL; Brodeur GM; Chou PM; Kwiatkowski JL; Babbo A; Cohn SL
    Cancer Res; 2000 Nov; 60(21):5966-71. PubMed ID: 11085514
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enlarged and prominent nucleoli may be indicative of MYCN amplification: a study of neuroblastoma (Schwannian stroma-poor), undifferentiated/poorly differentiated subtype with high mitosis-karyorrhexis index.
    Kobayashi C; Monforte-Munoz HL; Gerbing RB; Stram DO; Matthay KK; Lukens JN; Seeger RC; Shimada H
    Cancer; 2005 Jan; 103(1):174-80. PubMed ID: 15549714
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Schwannian cell differentiation of human neuroblastoma cell lines in vitro induced by bromodeoxyuridine.
    Sugimoto T; Kato T; Sawada T; Horii Y; Kemshead JT; Hino T; Morioka H; Hosoi H
    Cancer Res; 1988 May; 48(9):2531-7. PubMed ID: 2833349
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neuroblastoma cells provoke Schwann cell proliferation in vitro.
    Ambros IM; Attarbaschi A; Rumpler S; Luegmayr A; Turkof E; Gadner H; Ambros PF
    Med Pediatr Oncol; 2001 Jan; 36(1):163-8. PubMed ID: 11464875
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Schwann cell-conditioned medium inhibits angiogenesis in vitro and in vivo.
    Huang D; Rutkowski JL; Brodeur GM; Chou PM; Kwiatkowski JL; Babbo A; Cohn SL
    Med Pediatr Oncol; 2000 Dec; 35(6):590-2. PubMed ID: 11107124
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SPARC is a key Schwannian-derived inhibitor controlling neuroblastoma tumor angiogenesis.
    Chlenski A; Liu S; Crawford SE; Volpert OV; DeVries GH; Evangelista A; Yang Q; Salwen HR; Farrer R; Bray J; Cohn SL
    Cancer Res; 2002 Dec; 62(24):7357-63. PubMed ID: 12499280
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Loss of heterozygosity for chromosome 14q in neuroblastoma.
    Thompson PM; Seifried BA; Kyemba SK; Jensen SJ; Guo C; Maris JM; Brodeur GM; Stram DO; Seeger RC; Gerbing R; Matthay KK; Matise TC; White PS
    Med Pediatr Oncol; 2001 Jan; 36(1):28-31. PubMed ID: 11464899
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Loss of heterozygosity for chromosomes 1 or 14 defines subsets of advanced neuroblastomas.
    Fong CT; White PS; Peterson K; Sapienza C; Cavenee WK; Kern SE; Vogelstein B; Cantor AB; Look AT; Brodeur GM
    Cancer Res; 1992 Apr; 52(7):1780-5. PubMed ID: 1551108
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of subsets of neuroblastomas by combined histopathologic and N-myc analysis.
    Shimada H; Stram DO; Chatten J; Joshi VV; Hachitanda Y; Brodeur GM; Lukens JN; Matthay KK; Seeger RC
    J Natl Cancer Inst; 1995 Oct; 87(19):1470-6. PubMed ID: 7674334
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Schwann cells in neuroblastoma.
    Ambros IM; Ambros PF
    Eur J Cancer; 1995; 31A(4):429-34. PubMed ID: 7576940
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multilocus loss of heterozygosity allelotypes identify a genetic pathway associated with progression from low to high stage disease in neuroblastoma.
    Chughtai SA; Genus T; Ramani P; Dyer S; Powell JE; McMullan D; Davison V; McConville CM;
    Eur J Cancer; 2006 Aug; 42(12):1826-34. PubMed ID: 16872824
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The calcium-sensing receptor and parathyroid hormone-related protein are expressed in differentiated, favorable neuroblastic tumors.
    de Torres C; Beleta H; Díaz R; Toran N; Rodríguez E; Lavarino C; García I; Acosta S; Suñol M; Mora J
    Cancer; 2009 Jun; 115(12):2792-803. PubMed ID: 19350667
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas.
    Guo C; White PS; Weiss MJ; Hogarty MD; Thompson PM; Stram DO; Gerbing R; Matthay KK; Seeger RC; Brodeur GM; Maris JM
    Oncogene; 1999 Sep; 18(35):4948-57. PubMed ID: 10490829
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A role for distinct cell types in determining malignancy in human neuroblastoma cell lines and tumors.
    Ross RA; Biedler JL; Spengler BA
    Cancer Lett; 2003 Jul; 197(1-2):35-9. PubMed ID: 12880957
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Systematization of primary histopathologic and fine-needle aspiration cytologic features and description of unusual histopathologic features of neuroblastic tumors: a report from the Pediatric Oncology Group.
    Joshi VV; Silverman JF; Altshuler G; Cantor AB; Larkin EW; Neill JS; Norris HT; Shuster JJ; Holbrook CT; Hayes FA
    Hum Pathol; 1993 May; 24(5):493-504. PubMed ID: 8491489
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative genetic study of intratumoral heterogenous MYCN amplified neuroblastoma versus aggressive genetic profile neuroblastic tumors.
    Berbegall AP; Villamón E; Piqueras M; Tadeo I; Djos A; Ambros PF; Martinsson T; Ambros IM; Cañete A; Castel V; Navarro S; Noguera R
    Oncogene; 2016 Mar; 35(11):1423-32. PubMed ID: 26119945
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.